Pathology

Lim Tze Peng

Assistant Professor, SingHealth Duke-NUS Pathology Academic Clinical Programme

tzepeng.lim@duke-nus.edu.sg

About

Professional

Research Interests

Publications

Bio

Dr Lim Tze Peng graduated in Pharmacy from the National University of Singapore (NUS) in Singapore in 2004. He then obtained his Ph.D. in Microbiology as a part-time student from NUS in 2014; while working as a hospital pharmacist. He is currently a Senior Principal Pharmacist Researcher at Singapore General Hospital and Assistant Professor at Duke-NUS Medical School.

Dr Lim had made important contributions to the field where he worked on extensively drug resistant bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae. His contributions included advancing the treatment options of extensively drug resistant bacteria that causes hospital acquired infections worldwide.

His work is aimed at identifying the optimal combination of antibiotics in the treatment of extensively drug resistant bacteria that causes hospital acquired infections worldwide. His work is national in scope in that infectious diseases cross all sectors of; it is intrinsically exemplary in that it seeks maximally effective treatments for deadly diseases and buys time for other scientists to develop new treatments. This has broad implications for other researchers and broad applications for clinicians. Dr Lim is the (co-) author of over 20 peer-reviewed publications and more than 40 abstracts in antimicrobial pharmacokinetics / pharmacodynamics and infectious disease therapeutics. He has also served as a journal reviewer for the Journal of Antibiotics, Medicine, Journal of Medical Microbiology, Singapore Medical Journal & Journal of Antimicrobial Chemotherapy.

Pathology

Bio

Education

Doctor of Medicine

Bachelor of Science (Pharmacy) with Hons

Professional Appointment(s)

Senior Principal Pharmacist Researcher

Research Interests

Publications

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.

Physicochemical Stability Study of Polymyxin B in Various Infusion Solutions for Administration to Critically Ill Patients.

In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.

In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.

Evaluating polymyxin B-based combinations against carbapenem-resistant Escherichia coli in time-kill studies and in a hollow-fiber infection model.

From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB)

Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.

Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours.

Multiple Genetic Mutations Associated with Polymyxin Resistance in Acinetobacter baumannii.

mcr-1 in Multidrug-Resistant blaKPC-2-Producing Clinical Enterobacteriaceae Isolates in Singapore.

Pathology

Bio

Education

Doctor of Medicine

Bachelor of Science (Pharmacy) with Hons

Professional Appointment(s)

Senior Principal Pharmacist Researcher

Research Interests

Publications

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.

Physicochemical Stability Study of Polymyxin B in Various Infusion Solutions for Administration to Critically Ill Patients.

In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.

In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.

Evaluating polymyxin B-based combinations against carbapenem-resistant Escherichia coli in time-kill studies and in a hollow-fiber infection model.

From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB)

Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.

Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours.

Multiple Genetic Mutations Associated with Polymyxin Resistance in Acinetobacter baumannii.

mcr-1 in Multidrug-Resistant blaKPC-2-Producing Clinical Enterobacteriaceae Isolates in Singapore.

Browser not supported

Modern websites need modern browsers